Glaxosmithkline Pharmaceuticals Ltd (GLAXO) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 793005,
    "name": "Glaxosmi. Pharma",
    "stock_name": "Glaxosmi. Pharma",
    "full_name": "Glaxosmithkline Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/glaxosmi-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "2,545.65",
    "chg": 36.35,
    "chgp": "1.45%",
    "dir": 1,
    "prev_price": "2,509.30",
    "mcapval": "43,124.85 Cr",
    "mcap": "Mid Cap",
    "scripcode": 500660,
    "symbol": "GLAXO",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE159A01016",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "1.35 lacs",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glaxosmi-pharma-793005-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Glaxosmi. Pharma’s Evaluation Revised Amidst Challenging Market Conditions",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmi-pharma-downgraded-to-sell-by-marketsmojo-amid-valuation-concerns-3731005",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GlaxosmiPharma_mojoScore_3731005.png",
        "date": "2025-11-26 09:46:20",
        "description": "Glaxosmi. Pharma has undergone a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor sentiment and stock performance within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Are Glaxosmi. Pharma latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-glaxosmi-pharma-latest-results-good-or-bad-3680521",
        "imagepath": "",
        "date": "2025-11-07 19:22:53",
        "description": "GlaxoSmithKline Pharmaceuticals reported its Q2 FY26 results, highlighting a complex operational landscape. The company achieved a net profit of ₹257.49 crores, reflecting a quarter-on-quarter growth of 25.60%, while year-on-year growth was modest at 1.98%. This indicates a strong performance in profitability, driven primarily by improved operational efficiencies.\n\nHowever, revenue for the same quarter was ₹979.94 crores, which represents a decline of 3.05% year-on-year, marking the second consecutive quarter of negative growth in this metric. Despite a significant quarter-on-quarter increase of 21.71%, the overall trend raises concerns about the sustainability of revenue generation in a competitive market.\n\nOperationally, the company demonstrated notable efficiency with an operating margin of 34.26%, the highest in eight quarters, attributed to better product mix management and effective cost control measu..."
      },
      {
        "title": "How has been the historical performance of Glaxosmi. Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-glaxosmi-pharma-3677204",
        "imagepath": "",
        "date": "2025-11-06 22:57:25",
        "description": "Answer:\nThe historical performance of Glaxosmi. Pharma shows a consistent growth trend in net sales and profitability over the years leading up to March 2025.\n\nBreakdown:\nGlaxosmi. Pharma's net sales have increased from 3,128.12 crore in March 2019 to 3,749.21 crore in March 2025, reflecting a steady upward trajectory. The total operating income followed a similar pattern, rising from 3,128.12 crore in March 2019 to 3,749.21 crore in March 2025. The company's operating profit (PBDIT) has also seen significant growth, climbing from 703.11 crore in March 2019 to 1,323.29 crore in March 2025, with an operating profit margin that improved from 19.21% to 31.4% over the same period. Profit before tax surged from 682.66 crore in March 2019 to 1,259.88 crore in March 2025, while profit after tax reached 927.58 crore in March 2025, up from 445.39 crore in March 2019. The earnings per share (EPS) increased notably fr..."
      },
      {
        "title": "Why is Glaxosmi. Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-glaxosmi-pharma-fallingrising-3676888",
        "imagepath": "",
        "date": "2025-11-06 22:36:27",
        "description": "As of 06-Nov, Glaxosmithkline Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 2,599.75, reflecting a decrease of 61.75 points or 2.32%. The stock has underperformed its sector by 1.55% today and has been on a downward trend for the last two days, accumulating a total loss of 3.19% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Despite a high management efficiency with a return on equity (ROE) of 42.32% and a low debt-to-equity ratio, the company faces challenges such as poor long-term growth, with net sales growing at an annual rate of only 3.92% over the last five years, and a high valuation compared to its peers, which may be contributing to the stock's recent decline.\n\nIn the broader market context, Glaxosmithkline's short-term performance has been relatively better th..."
      },
      {
        "title": "GlaxoSmithKline Pharmaceuticals Q2 FY26: Premium Valuation Under Pressure as Growth Stalls",
        "link": "https://www.marketsmojo.com/news/result-analysis/glaxosmithkline-pharmaceuticals-q2-fy26-premium-valuation-under-pressure-as-growth-stalls-3677787",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/Glaxosmithkline_quaterlyResult_3677787.png",
        "date": "2025-11-06 19:33:12",
        "description": "GlaxoSmithKline Pharmaceuticals Ltd. reported a modest net profit of ₹257.49 crores for Q2 FY26, marking a 25.60% quarter-on-quarter increase but a mere 1.98% year-on-year growth. The pharmaceutical major, with a market capitalisation of ₹44,633 crores, continues to grapple with anaemic top-line expansion whilst maintaining its premium valuation at 47 times trailing earnings. The stock has declined 2.32% following the results announcement, trading at ₹2,599.75 and reflecting investor concerns about the sustainability of its lofty multiples in the face of stagnating revenue growth."
      },
      {
        "title": "Is Glaxosmi. Pharma technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-glaxosmi-pharma-technically-bullish-or-bearish-3660460",
        "imagepath": "",
        "date": "2025-10-31 08:28:38",
        "description": "As of 30 October 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish Bollinger Bands on both weekly and monthly time frames, and bearish moving averages on the daily chart. The KST is also bearish on the weekly, contributing to the overall bearish sentiment. Although the Dow Theory shows a mildly bearish weekly outlook and a bullish monthly perspective, the prevailing bearish indicators suggest a negative short-term trend for Glaxosmi. Pharma...."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Adjusts Evaluation Amid Mixed Financial Indicators and Market Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-stock-downgraded-from-hold-to-sell-by-marketsmojo-3637077",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/Glaxosmithkline_mojoScore_3637077.png",
        "date": "2025-10-21 08:41:57",
        "description": "Glaxosmithkline Pharmaceuticals has recently experienced an evaluation adjustment, indicating a shift in its technical indicators. While the stock has performed well year-to-date, its annual return is modest compared to profit growth. The company faces challenges with a high Price to Book Value ratio and flat quarterly results."
      },
      {
        "title": "Is Glaxosmi. Pharma technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-glaxosmi-pharma-technically-bullish-or-bearish-3636903",
        "imagepath": "",
        "date": "2025-10-21 08:24:11",
        "description": "As of 20 October 2025, the technical trend for Glaxosmi. Pharma has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the weekly MACD and KST indicators both showing bearish signals, while the monthly MACD and KST are only mildly bearish. The daily moving averages are also bearish, indicating short-term weakness. The Bollinger Bands present a mixed picture with a mildly bearish outlook on the weekly and bullish on the monthly. The OBV shows a mildly bullish trend on the monthly, suggesting some accumulation. Overall, the lack of strong bullish signals and the presence of bearish indicators suggest caution in the current market environment...."
      },
      {
        "title": "How has been the historical performance of Glaxosmi. Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-glaxosmi-pharma-3636109",
        "imagepath": "",
        "date": "2025-10-20 22:42:50",
        "description": "Answer:\nThe historical performance of Glaxosmi. Pharma shows a steady growth in net sales and profitability over the years, with significant fluctuations in certain metrics.\n\nBreakdown:\nGlaxosmi. Pharma's net sales have increased from 3,128.12 Cr in Mar'19 to 3,749.21 Cr in Mar'25, reflecting a consistent upward trend. The total operating income followed a similar trajectory, rising from 3,128.12 Cr in Mar'19 to 3,749.21 Cr in Mar'25. The company's operating profit (PBDIT) has also shown improvement, climbing from 703.11 Cr in Mar'19 to 1,323.29 Cr in Mar'25, with an operating profit margin that increased from 19.21% to 31.4% over the same period. Profit before tax reached 1,259.88 Cr in Mar'25, up from 682.66 Cr in Mar'19, while profit after tax saw a notable rise to 927.58 Cr in Mar'25 from 445.39 Cr in Mar'19. The earnings per share (EPS) surged from 26.29 in Mar'19 to 54.75 in Mar'25, indicating enhance..."
      }
    ],
    "total": 5143,
    "sid": "793005",
    "stock_news_url": "https://www.marketsmojo.com/news/glaxosmithkline-pharmaceuticals-793005"
  },
  "announcements": [
    {
      "caption": "Disclosure Under Regulation 30",
      "datetime": "19-Nov-2025",
      "details": "As per attachment",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "10-Nov-2025",
      "details": "As per attachment",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
      "datetime": "10-Nov-2025",
      "details": "As per attachment",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Glaxosmithkline Pharmaceuticals Ltd has declared <strong>420%</strong> dividend, ex-date: 30 May 25",
          "dt": "2025-05-30",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Glaxosmithkline Pharmaceuticals Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 11 Sep 18",
          "dt": "2018-09-11",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Glaxosmi. Pharma’s Evaluation Revised Amidst Challenging Market Conditions

2025-11-26 09:46:20

Glaxosmi. Pharma has undergone a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor sentiment and stock performance within the Pharmaceuticals & Biotechnology sector.

Are Glaxosmi. Pharma latest results good or bad?

2025-11-07 19:22:53

GlaxoSmithKline Pharmaceuticals reported its Q2 FY26 results, highlighting a complex operational landscape. The company achieved a net profit of ₹257.49 crores, reflecting a quarter-on-quarter growth of 25.60%, while year-on-year growth was modest at 1.98%. This indicates a strong performance in profitability, driven primarily by improved operational efficiencies. However, revenue for the same quarter was ₹979.94 crores, which represents a decline of 3.05% year-on-year, marking the second consecutive quarter of negative growth in this metric. Despite a significant quarter-on-quarter increase of 21.71%, the overall trend raises concerns about the sustainability of revenue generation in a competitive market. Operationally, the company demonstrated notable efficiency with an operating margin of 34.26%, the highest in eight quarters, attributed to better product mix management and effective cost control measu...

How has been the historical performance of Glaxosmi. Pharma?

2025-11-06 22:57:25

Answer: The historical performance of Glaxosmi. Pharma shows a consistent growth trend in net sales and profitability over the years leading up to March 2025. Breakdown: Glaxosmi. Pharma's net sales have increased from 3,128.12 crore in March 2019 to 3,749.21 crore in March 2025, reflecting a steady upward trajectory. The total operating income followed a similar pattern, rising from 3,128.12 crore in March 2019 to 3,749.21 crore in March 2025. The company's operating profit (PBDIT) has also seen significant growth, climbing from 703.11 crore in March 2019 to 1,323.29 crore in March 2025, with an operating profit margin that improved from 19.21% to 31.4% over the same period. Profit before tax surged from 682.66 crore in March 2019 to 1,259.88 crore in March 2025, while profit after tax reached 927.58 crore in March 2025, up from 445.39 crore in March 2019. The earnings per share (EPS) increased notably fr...

Why is Glaxosmi. Pharma falling/rising?

2025-11-06 22:36:27

As of 06-Nov, Glaxosmithkline Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 2,599.75, reflecting a decrease of 61.75 points or 2.32%. The stock has underperformed its sector by 1.55% today and has been on a downward trend for the last two days, accumulating a total loss of 3.19% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Despite a high management efficiency with a return on equity (ROE) of 42.32% and a low debt-to-equity ratio, the company faces challenges such as poor long-term growth, with net sales growing at an annual rate of only 3.92% over the last five years, and a high valuation compared to its peers, which may be contributing to the stock's recent decline. In the broader market context, Glaxosmithkline's short-term performance has been relatively better th...

GlaxoSmithKline Pharmaceuticals Q2 FY26: Premium Valuation Under Pressure as Growth Stalls

2025-11-06 19:33:12

GlaxoSmithKline Pharmaceuticals Ltd. reported a modest net profit of ₹257.49 crores for Q2 FY26, marking a 25.60% quarter-on-quarter increase but a mere 1.98% year-on-year growth. The pharmaceutical major, with a market capitalisation of ₹44,633 crores, continues to grapple with anaemic top-line expansion whilst maintaining its premium valuation at 47 times trailing earnings. The stock has declined 2.32% following the results announcement, trading at ₹2,599.75 and reflecting investor concerns about the sustainability of its lofty multiples in the face of stagnating revenue growth.

Is Glaxosmi. Pharma technically bullish or bearish?

2025-10-31 08:28:38

As of 30 October 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish Bollinger Bands on both weekly and monthly time frames, and bearish moving averages on the daily chart. The KST is also bearish on the weekly, contributing to the overall bearish sentiment. Although the Dow Theory shows a mildly bearish weekly outlook and a bullish monthly perspective, the prevailing bearish indicators suggest a negative short-term trend for Glaxosmi. Pharma....

Glaxosmithkline Pharmaceuticals Adjusts Evaluation Amid Mixed Financial Indicators and Market Trends

2025-10-21 08:41:57

Glaxosmithkline Pharmaceuticals has recently experienced an evaluation adjustment, indicating a shift in its technical indicators. While the stock has performed well year-to-date, its annual return is modest compared to profit growth. The company faces challenges with a high Price to Book Value ratio and flat quarterly results.

Is Glaxosmi. Pharma technically bullish or bearish?

2025-10-21 08:24:11

As of 20 October 2025, the technical trend for Glaxosmi. Pharma has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the weekly MACD and KST indicators both showing bearish signals, while the monthly MACD and KST are only mildly bearish. The daily moving averages are also bearish, indicating short-term weakness. The Bollinger Bands present a mixed picture with a mildly bearish outlook on the weekly and bullish on the monthly. The OBV shows a mildly bullish trend on the monthly, suggesting some accumulation. Overall, the lack of strong bullish signals and the presence of bearish indicators suggest caution in the current market environment....

How has been the historical performance of Glaxosmi. Pharma?

2025-10-20 22:42:50

Answer: The historical performance of Glaxosmi. Pharma shows a steady growth in net sales and profitability over the years, with significant fluctuations in certain metrics. Breakdown: Glaxosmi. Pharma's net sales have increased from 3,128.12 Cr in Mar'19 to 3,749.21 Cr in Mar'25, reflecting a consistent upward trend. The total operating income followed a similar trajectory, rising from 3,128.12 Cr in Mar'19 to 3,749.21 Cr in Mar'25. The company's operating profit (PBDIT) has also shown improvement, climbing from 703.11 Cr in Mar'19 to 1,323.29 Cr in Mar'25, with an operating profit margin that increased from 19.21% to 31.4% over the same period. Profit before tax reached 1,259.88 Cr in Mar'25, up from 682.66 Cr in Mar'19, while profit after tax saw a notable rise to 927.58 Cr in Mar'25 from 445.39 Cr in Mar'19. The earnings per share (EPS) surged from 26.29 in Mar'19 to 54.75 in Mar'25, indicating enhance...

View All News